+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05483400

Phase 2 Open Label Study of Atezolizumab and Tiragolumab Treatment in Patients with Head and Neck Cancer, MSI-H Cancer, Metastatic Melanoma, and Other Advanced Solid Tumors

Led by University Medical Center Groningen · Updated on 2025-03-30

97

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination of two immunotherapy drugs, atezolizumab anti-PD-L1 antibody and tiragolumab anti-TIGIT antibody, in patients with various solid tumors. This open-label phase II trial includes patients with localized head and neck squamous cell carcinoma HNSCC undergoing surgery, advanced or metastatic microsatellite instability-high MSI-H cancer, PD-1 resistant metastatic melanoma, and those with locally advanced or metastatic solid tumors who might benefit from this treatment. The goal is to assess the anti-tumor activity, safety, and tolerability of this combination and explore protein markers that might predict treatment response. Participants will receive intravenous infusions of tiragolumab 1200 mg plus atezolizumab 600 mg every three weeks. Treatment continues until surgery after two courses for HNSCC patients, resectable disease in MSI-H tumors, disease progression or side effects, or a maximum of two years. Tissue samples will be collected at baseline, during treatment, and at surgery. Blood samples will monitor circulating tumor DNA, and imaging scans CT or MRI will track tumor response. Throughout the trial, participants will undergo regular evaluations including tumor biopsies, imaging to measure treatment response, and laboratory tests to monitor safety and immune markers. The primary outcomes are pathological response in HNSCC patients at surgery and radiological response in other cohorts. Secondary outcomes include safety assessments, disease-free survival, progression-free survival, overall response rates, duration of response, and correlation of specific protein expressions with treatment outcomes. The study is led by the University Medical Center Groningen and will continue until 2027.

CONDITIONS

Brief Title

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

Research Team

D

Derk JA de Groot, Md PhD

D

Daan G Knapen, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here